IMQUEST PHARMACEUTICALS LICENSES ENTIRE SERIES OF ANTI-HIV THERAPEUTIC COMPOUNDS FROM SAMJIN PHARMACEUTICAL CO.

ImQuest Pharmaceuticals, Inc. announced today the licensing of the entire pyrimidinedione series of anti-HIV compounds discovered and patented by Samjin Pharmaceutical Co. Ltd. ImQuest plans to develop the lead inhibitor in this series as a front-line therapy for HIV infection. The pyrimidinediones are unique compounds that posess two highly effective mechanisms of action against HIV; inhibition of reverse transcriptase (RT), and inhibition of virus entry into target cells.

Yahoo News (http://biz.yahoo.com/prnews/060228/nytu093.html?.v=38)